中国基层医药
中國基層醫藥
중국기층의약
Chinese Journal of Primary Medicine and Pharmacy
2015年
22期
3470-3472
,共3页
舒肝解郁胶囊%艾司西酞普兰%卒中%抑郁
舒肝解鬱膠囊%艾司西酞普蘭%卒中%抑鬱
서간해욱효낭%애사서태보란%졸중%억욱
Shugan -jieyu capsule%Escitalopram%Post -stroke%Depression
目的：探讨舒肝解郁胶囊联合艾司西酞普兰治疗卒中后抑郁（PSD）的疗效。方法将80例PSD 患者按数字表法随机分为研究组、对照组，每组40例。研究组采用舒肝解郁胶囊联合艾司西酞普兰治疗，对照组单用艾司西酞普兰片治疗，两组患者均治疗8周。在治疗前及治疗后的2、4、8周末分别评定汉密尔顿抑郁量表（HAMD）、改良爱丁堡-斯堪的纳维亚评分量表（MESSS）及副反应量表（TESS）评分，比较两组临床疗效。结果研究组第4、8周末 HAMD 评分分别为（16．92±3．75）分、（8．60±3．25）分，均明显低于对照组的（19．27±4．11）分、（11．13±3．72）分（t2周＝－2．671，t4周＝－3．239，均 P ＜0．05）；研究组第4、8周末MESSS 量表得分分别为（20．06±3．87）分、（12．47±3．97）分，均明显低于对照组的（21．68±3．12）分、（15．09±3．20）分（t2周＝－2．061，t4周＝－3．250，均 P ＜0．05）。研究组疗程结束后的显效率80．0％，明显高于对照组的45．0％（χ2＝5．227，P ＜0．05）。结论舒肝解郁胶囊联合艾司西酞普兰治疗卒中后抑郁的疗效优于单用艾司西酞普兰。
目的：探討舒肝解鬱膠囊聯閤艾司西酞普蘭治療卒中後抑鬱（PSD）的療效。方法將80例PSD 患者按數字錶法隨機分為研究組、對照組，每組40例。研究組採用舒肝解鬱膠囊聯閤艾司西酞普蘭治療，對照組單用艾司西酞普蘭片治療，兩組患者均治療8週。在治療前及治療後的2、4、8週末分彆評定漢密爾頓抑鬱量錶（HAMD）、改良愛丁堡-斯堪的納維亞評分量錶（MESSS）及副反應量錶（TESS）評分，比較兩組臨床療效。結果研究組第4、8週末 HAMD 評分分彆為（16．92±3．75）分、（8．60±3．25）分，均明顯低于對照組的（19．27±4．11）分、（11．13±3．72）分（t2週＝－2．671，t4週＝－3．239，均 P ＜0．05）；研究組第4、8週末MESSS 量錶得分分彆為（20．06±3．87）分、（12．47±3．97）分，均明顯低于對照組的（21．68±3．12）分、（15．09±3．20）分（t2週＝－2．061，t4週＝－3．250，均 P ＜0．05）。研究組療程結束後的顯效率80．0％，明顯高于對照組的45．0％（χ2＝5．227，P ＜0．05）。結論舒肝解鬱膠囊聯閤艾司西酞普蘭治療卒中後抑鬱的療效優于單用艾司西酞普蘭。
목적：탐토서간해욱효낭연합애사서태보란치료졸중후억욱（PSD）적료효。방법장80례PSD 환자안수자표법수궤분위연구조、대조조，매조40례。연구조채용서간해욱효낭연합애사서태보란치료，대조조단용애사서태보란편치료，량조환자균치료8주。재치료전급치료후적2、4、8주말분별평정한밀이돈억욱량표（HAMD）、개량애정보-사감적납유아평분량표（MESSS）급부반응량표（TESS）평분，비교량조림상료효。결과연구조제4、8주말 HAMD 평분분별위（16．92±3．75）분、（8．60±3．25）분，균명현저우대조조적（19．27±4．11）분、（11．13±3．72）분（t2주＝－2．671，t4주＝－3．239，균 P ＜0．05）；연구조제4、8주말MESSS 량표득분분별위（20．06±3．87）분、（12．47±3．97）분，균명현저우대조조적（21．68±3．12）분、（15．09±3．20）분（t2주＝－2．061，t4주＝－3．250，균 P ＜0．05）。연구조료정결속후적현효솔80．0％，명현고우대조조적45．0％（χ2＝5．227，P ＜0．05）。결론서간해욱효낭연합애사서태보란치료졸중후억욱적료효우우단용애사서태보란。
Objective To explore the efficacy of shugan -jieyu capsule and escitalopram in treating post -stroke depression (PSD).Methods 80 cases with PSD were randomly divided into the study group(administered with shugan -jieyu capsule and escitalopram)and the control group(administered only with escitalopram),40 cases in each group.Hamilt Depression Rating Scale(HAMD),Modified Einberg -Scandinavian Stroke Scale(MESSS)and Treatment Emergent Symptoms Scale(TESS)were used to assess treatment effect before treatment and at the weekend of 2nd,4th,8th after treatment.Results The scores of HAMD and MESSS in the study group were much lower than those in the control group.The scores of HAMD at 4th weekend and 8th weekend in the study group were (16.92 ± 3.75),(8.60 ±3.25),those in the control group were (19.27 ±4.11),(11.13 ±3.72)(t2w =-2.671,t4w =-3.239,P <0.05).The scores of MESSS at 4th weekend and 8th weekend in the study group were (20.06 ±3.87), (12.47 ±3.97),which in the control group were (21.68 ±3.12),(15.09 ±3.20)(t2w =-2.061,t4w =-3.250, P <0.05),while the effective rate in the study group(80.0%)was significantly higher than that in the control group (45.0%)(χ2 =5.227,P <0.05).Conclusion The efficacy of shugan -jieyu capsule combined with escitalopram for PSD is superior to use escitalopram alone.
